Novo’s Wegovy Excels But Lilly Rival Hot On Heels
Obesity Sales Up 107%
After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.
You may also be interested in...
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.
The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.